Healthcare, Pharma & Life Sciences

Berlin – November 06, 2026 -- Germany's Innovation Fund has paid out more than €2 billion since 2016, yet only 24% of its completed new-care-model projects received a decision to examine continuation in routine care, according to AOK-Bundesverband. The statutory health insurer presented its proposals at a congress marking the fund's tenth anniversary, hosted by the Innovation Committee at the Federal Joint Committee (G-BA).

Half of 146 completed care-model projects received no recommendation

The fund has supported more than 850 projects. Of these, 270 fall under new care models and 591 under health services research. Half of the 146 completed new-care-model projects received no recommendation for further use.

New York – November 06, 2026 -- Kos Biotechnology Partners has invested in Fathom Therapeutics' oversubscribed $55 million Series A, which was led by Sutter Hill Ventures, to back a drug discovery platform that combines quantum chemistry, physics-based simulation and artificial intelligence.

Kos commits capital through its inaugural life sciences fund

The investment came through Kos BioVentures, the firm's first life sciences fund. Kos, based in New York and Athens, manages $125 million in assets. It invests across all development stages in therapeutic breakthroughs, biodefense and tech-enabled pharma services.

Cambridge, Mass. – November 06, 2026 -- CREATE Medicines, Inc. says it has treated more than 80 patients with in vivo CAR therapy, which it describes as the largest clinical dataset in the field. The company is now taking its four clinical-stage programs to investors and prospective partners at the Jefferies Global Healthcare Conference in London.

CREATE schedules one-on-one meetings at Jefferies London on Nov. 16-19, 2026

Management will hold one-on-one meetings at the Waldorf Hilton and ME London during the conference, which runs from Nov. 16 to 19, 2026. CEO and Co-Founder Daniel Getts, PhD, and Chief Medical Officer Matthew Maurer, MD, will represent the clinical-stage biotech.

Investors must request meetings through their Jefferies representative. Prospective partners can contact the company's business development team directly.

Guangzhou – November 06, 2026 -- China's National Medical Products Administration (NMPA) has approved Bio-Thera Solutions' BAT2506, the first golimumab biosimilar cleared in the country, the Shanghai-listed company (688177.SH) said.

ASHULI is cleared for rheumatoid arthritis and ankylosing spondylitis

BAT2506 will be sold in China under the brand name ASHULI. The NMPA approved it for two indications: rheumatoid arthritis and ankylosing spondylitis.

Golimumab is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF-α). Binding to TNF-α reduces the inflammatory markers CRP, IL-6, ICAM-1, MMP-3 and VEGF.

Bio-Thera adds its sixth approved biosimilar in China

CEO Shengfeng Li said ASHULI is the company's sixth biosimilar approved in China. He said biosimilars "have an important role in expanding patient access to important biologics."

SAN FRANCISCO – November 06, 2026 -- Avive Solutions, Inc. will deploy 25 Avive Connect AEDs as First Aid Sponsor of the 2026 Good Life Halfsy, Nebraska's largest half marathon, where 9,500 registered runners and more than 20,000 spectators are expected.

The 13th annual event in Lincoln, Nebraska, is projected to generate a $3.4 million economic impact for the region. Producer Pink Gorilla Events has generated more than $1.1 million in donations to local charities and nonprofits through its races.

Medical volunteers will carry Avive AEDs along the 13.1-mile course

The event's medical volunteers will carry the devices, putting them in the hands of trained responders along the route. A Good Life Halfsy co-race director said the added units are meant to strengthen race-day emergency preparedness for runners, spectators and volunteers.

Laval – November 06, 2026 -- Only 62.0% of patients hospitalized with severe alcohol-associated hepatitis (AH) in the United States were estimated to survive 12 months, according to a real-world study from Bausch Health Companies Inc. and its gastroenterology unit, Salix Pharmaceuticals.

Study of 1,630 US adults tracks rehospitalization and transplant rates

The companies are presenting the poster, "Clinical Burden and Outcomes in a Large Real-World Cohort of Patients Hospitalized with Severe Alcohol-Associated Hepatitis," at the American Association for the Study of Liver Diseases' The Liver Meeting 2026. The meeting runs November 5-9 in Denver, Colorado. The cohort comprised 1,630 adults.

Rehospitalization climbs from 31.4% at 30 days to 69.1% at 12 months

Within 30 days of discharge, 31.4% of patients were rehospitalized. The estimated rate reached 69.1% by 12 months. The estimated liver transplantation rate at 12 months was 8.5%.

Boston – November 06, 2026 -- Servier will present nine abstracts, including five oral presentations, at the 31st Society for Neuro-Oncology (SNO) Annual Meeting, held November 12-15 in Philadelphia. The package covers both of its glioma therapies: VORANIGO (vorasidenib) in IDH-mutant glioma and OJEMDA (tovorafenib) in BRAF-altered pediatric low-grade glioma (pLGG).

Four-year FIREFLY-1 data to cover retreatment after progression in pLGG

One oral presentation will deliver updated results from the four-year follow-up of the Phase 2 FIREFLY-1 study of OJEMDA in relapsed or refractory BRAF-altered pLGG. The analysis includes data on post-treatment observation and on retreatment with OJEMDA after disease progression.

New York – November 06, 2026 -- NYU Langone Health's Leon H. Charney Division of Cardiology will deliver more than 75 presentations, on-demand discussions and poster sessions at the American Heart Association (AHA) Scientific Sessions 2026, held November 6 to 9 in Chicago. Four of its studies are slotted into Late-Breaking Science and Featured Science sessions.

PARSIPPANY, N.J. – November 06, 2026 -- Onkos Surgical has received its fourth FDA 510(k) clearance for NanoCept Antibacterial Technology since the coating won De Novo authorization in April 2024, extending it to more titanium components of the ELEOS Limb Salvage System.

Clearance covers femurs, tibial baseplates and stems

The new clearance adds proximal femurs, tibial baseplates and augments, and cemented bowed segmental stems to the NanoCept portfolio. It also permits broader NanoCept coverage on titanium components that were previously cleared.

The decision follows an earlier clearance this year that applied NanoCept to titanium implants.

Geneva – November 06, 2026 -- iOnctura's chemo-free regimen of roginolisib plus dostarlimab produced grade 3 or higher treatment-emergent adverse events in 35% of patients with immunotherapy-resistant non-small cell lung cancer (NSCLC), against 75% in the chemotherapy-containing control arm, according to late-breaking Phase I/II PULMO-01 data presented at the SITC 2026 Annual Meeting.

The triplet arm, which added docetaxel to roginolisib and dostarlimab, recorded a 69% rate. No fatal adverse events were attributed to roginolisib.